Eliciting cytotoxic T-lymphocyte responses from synthetic vectors containing one or two epitopes in a C57BL/6 mouse model using peptide-containing biodegradable microspheres and adjuvants

Vaccine

Volumn 32, Issue 33, 2014, Pages 4111-4116

  Rubsamen, R M ^a,b   Herst, C V ^a   Lloyd, P M ^a   Heckerman, D E ^c  

^a Flow Pharma Inc   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c MICROSOFT RESEARCH   (United States)

Author keywords

ELISPOT; Epitope; Mouse; OVA; TLR 4; TLR 9; VSV

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; DRUG CARRIER; EPITOPE; GAMMA INTERFERON; IMMUNOLOGICAL ADJUVANT; MICROSPHERE; OVALBUMIN; PHOSPHORYL LIPID A; POLYGLACTIN; POLYSTYRENE; TOLL LIKE RECEPTOR 4; CPG-OLIGONUCLEOTIDE; OLIGODEOXYRIBONUCLEOTIDE; POLYGLYCOLIC ACID; TOLL LIKE RECEPTOR 9; VACCINE;

ANIMAL EXPERIMENT; ANTIGEN PRESENTATION; ARTICLE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG DELIVERY SYSTEM; ENZYME LINKED IMMUNOSPOT ASSAY; IMMUNE RESPONSE; MACROPHAGE; MICROENCAPSULATION; MOUSE; NONHUMAN; PARTICLE SIZE; PHAGOCYTOSIS; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; SALMONELLA MINNESOTA; SPLEEN CELL; SPRAY DRYING; VESICULAR STOMATITIS VIRUS; AGONISTS; ANIMAL; C57BL MOUSE; IMMUNOLOGY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ENZYME-LINKED IMMUNOSPOT ASSAY; EPITOPES, T-LYMPHOCYTE; MICE, INBRED C57BL; MICROSPHERES; OLIGODEOXYRIBONUCLEOTIDES; POLYGLYCOLIC ACID; T-LYMPHOCYTES, CYTOTOXIC; TOLL-LIKE RECEPTOR 4; TOLL-LIKE RECEPTOR 9; VACCINES;

EID: 84903461240     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.05.071     Document Type: Article

References (40)

1. Virgin H.W., Walker B.D. Immunology and the elusive AIDS vaccine. Nature 2010, 464.
2. Létourneau S., Im E.J., Mashishi T., Brereton C., Bridgeman A., Yang H., et al. Design and pre-clinical evaluation of a universal HIV-1 vaccine. PLoS One 2007, 2.
3. Rolland M., Nickle D., Mullins J. HIV-1 group M conserved elements vaccine. PLoS Pathog 2007, 3.
4. Kresge K.J., McEnery R. Canvassing CROI. IAVI Report 2009, 13.
5. Dinges W.L., Richardt J., Friedrich D., Jalbert E., Liu Y., Stevens C.E., et al. Virus-specific CD8+ T-cell responses better define HIV disease progression than HLA genotype. J Virol 2010, 84.
6. Dahirel V., Shekhar K., Pereyra F., Miura T., Artyomov M., Talsania S., et al. Coordinate linkage of HIV evolution reveals regions of immunological vulnerability. Proc Natl Acad Sci U S A 2011, 108.
7. Mothe B., Llano A., Ibarrondo J., Daniels M., Miranda C., Zamarreño J., et al. Definition of the viral targets of protective HIV-1-specific T cell responses. J Transl Med BioMed Central Ltd 2011, 9.
8. Mothe B., Llano A., Ibarrondo J., Zamarreno J., Schiaulini M., Miranda C., et al. CTL responses of high functional avidity and broad variant cross-reactivity are associated with HIV control. PLoS ONE 2012, 7(1).
9. Ferguson A.L., Mann J.K., Omarjee S., Ndung'u T., Walker B.D., Chakraborty A.K. Translating HIV sequences into quantitative fitness landscapes predicts viral vulnerabilities for rational immunogen design. Immunity 2013, 21.
10. Mothe B. DNA-MVA Prime-Boost Vaccine Eliciting T-Cell Specificities Associated with HIV-1 Control is Highly Immunogenic in Mice and Breaks CTL Immunodominance. AIDS Vaccine 2013. Barcelona, Spain 2013.
11. Mullins J. Refocusing CTL and Antibody Responses with p24gag Conserved Elements Vaccines. AIDS Vaccine. Barcelona, Spain 2013.
12. Wang F., Ono T., Kalergis A., Zhang W., DiLorenzo T., Lim K. On defining the rules for interactions between the T cell receptor and its ligand: a critical role for a specific amino acid residue of the T cell receptor b chain. Proc Natl Acad Sci U S A 1998, 95(6).
13. Schlosser E., Mueller M., Groettrup M. TLR ligands and antigen need to be coencapsulated into the same biodegradable microsphere for the generation of potent cytotoxic T lymphocyte responses. Vaccine 2008, 11.
14. Waeckerle-Men Y., Allmen E.U., Gander B., Scandella E., Schlosser E., Schmidtke G., et al. Encapsulation of proteins and peptides into biodegradable poly(D,L-lactide-co-glycolide) microspheres prolongs and enhances antigen presentation by human dendritic cells. Vaccine 2006, 24.
15. Martín-Banderas L.F., lores-Mosquera M., Riesco-Chueca P., Rodríguez-Gil A., Cebolla A., Chávez S. Flow Focusing: a versatile technology to produce size-controlled and specific-morphology microparticles. Small 2005, 4.
16. Streeck H., Frahm N., Walker B. The role of IFN-γ Elispot assay in HIV vaccine research. Nat Protoc 2009, 9.
17. Rhee E. TLR4 ligands augment antigen-specific CD8+ T lymphocyte responses elicited by a viral vector vaccine. J Virol 2010, 7.
18. Harandi A., Davies G., Olesen O. Vaccine adjuvants: scientific challenges and strategic initiatives. Expert Rev Vaccines 2009, 6.
19. Fox C., Friede M., Reed S., Ireton G. Synthetic and natural TLR4 agonists as safe and effective vaccine adjuvants. Subcell Biochem 2010, 18.
20. Steinhagen F. TLR-based immune adjuvants. Vaccine 2011, 12.
21. Bode C. CpG DNA as a vaccine adjuvant. Expert Rev Vaccines 2011, 13.
22. Lipford G., Bauer M., Blank C., Reiter R., Wagner H., Heeg K. CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants. Eur J Immun 2005, 5.
23. Ramaprakash H., Hogaboam C. CpG therapy attenuated experimental fungal asthma in a TLR9-dependent and independent manner. Allergy Immun 2010, 14.
24. Schlosser E., Mueller M., Groettrup M. TLR ligands and antigen need to be coencapsulated into the same biodegradable microsphere for the generation of potent cytotoxic T lymphocyte responses. Vaccine 2008, 11.
25. Newman K. Ovalbumin peptide encapsulated in Poly (d.l lactic-co-glycolic acid) microspheres is capable of inducing a T helper type 1 immune response. Control Release 1998, 11.
26. Newman K., Sosnowski D., Kwon G., Samuell J. Delivery of MUC1 mucin peptide by Poly(d,l-lactic-co-glycolic acid) microspheres induces type 1 T helper immune responses. J Pharm Sci 1998, 87(November (11)):7.
27. Whitton J., Sheng N., Oldstone M., McKee T. A "string-of-beads" vaccine, comprising linked minigenes, confers protection from lethal-dose virus challenge. J Virol 1992, 67(September (1)):5.
28. Kopycinski J., Cheeseman H., Ashraf A., Gill D., Hayes P., Hannaman D., et al. A DNA-based candidate HIV vaccine delivered via in vivo electroporation induces CD4 responses toward the α4β 7-binding V2 loop of HIV gp120 in healthy volunteers. Clin Vaccine Immunol 2012, 19(9).
29. De Groot A., Marcon L., Bishop E., Rivera D., Kutzler M., Weiner D., et al. HIV vaccine development by computer assisted design: the GAIA vaccine. Vaccine 2005, 18(March (23)):12.
30. Jain S., O'Hagan D., Singh M. The long-term potential of biodegradable poly(lactideco-glycolide) microparticles as the next-generation vaccine adjuvant. Expert Rev Vaccines 2011, 11.
31. Kanchan V., Panda A. Interactions of antigen-loaded polylactide particles with macrophages and their correlation with the immune response. Biomaterials 2007, 28:13.
32. Akagi T., Baba M., Akashi M. Biodegradable nanoparticles as vaccine adjuvants and delivery systems: regulation of immune responses by nanoparticle-based vaccine. Adv Polym Sci 2011, 247(33).
33. HogenEsch H. Mechanisms of stimulation of the immune response by aluminum adjuvants. Vaccine 2002, 6.
34. Irvine D., Swartz M., G S. Biomaterials-based vaccine technologies in commercial development. Nat Biomater 2013, 12(12).
35. Cooper S., Erickson A., Adams E., Kansopon J., Weiner A., Chien D. Analysis of a successful immune response against hepatitis C virus. Immunity 1999, 11.
36. Gruner N., Gerlach T., Jung M., Diepolder H. Association of hepatitis C virus-specific CD8+ T cells with viral clearance in acute hepatitis. J Infect Dis 2000, 9.
37. Lechner F., Wong D., Dunbar P., Chapman R., Chung R., Dohrenwend P. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 2000, 14.
38. Takaki A., Wiese M., Maertens G., Depla E., Seifert U., Liebetrau A. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med 2000, 5.
39. Epstein S. Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. Vaccine 2005, 7.
40. Doherty P., Kelso A. Toward a broadly protective influenza vaccine. J Clin Investig 2008, 3.